Allos Therapeutics Reports Fourth Quarter And Full Year 2011 Financial Results
In May 2011, Allos entered into a strategic collaboration agreement with Mundipharma International Corporation Limited (Mundipharma) and received an upfront payment of $50 million. License and other revenue related to the Mundipharma agreement for the fourth quarter and full year 2011 were $1.5 million and $30.6 million, respectively. As of December 31, 2011, $20.3 million was recorded as deferred revenue related to the Mundipharma agreement.
Cost of sales for the fourth quarter and full year 2011 were $1.3 million and $4.5 million, respectively, compared to $1.3 million and $3.6 million for the same periods in 2010.
Cost of license and other revenue for the fourth quarter and full year 2011 were $0.7 million and $11.7 million, respectively. The amount recorded for the full year 2011 was primarily related to the Company’s payment of $10.0 million (or 20% of the $50 million upfront payment the Company received from Mundipharma) to the licensors of FOLOTYN under the terms of the Company’s license agreement with Memorial Sloan-Kettering Cancer Center, SRI International, and Southern Research Institute.
Research and development (R&D) expenses for the fourth quarter and full year 2011 were $4.6 million and $22.2 million, respectively, compared to $8.3 million and $31.4 million for the same periods in 2010. R&D expenses for full year 2011 include $3.4 million of non-cash stock-based compensation expense.Selling, general and administrative (SG&A) expenses for the fourth quarter and full year 2011 were $11.4 million and $67.8 million, respectively, compared to $21.6 million and $78.8 million for the same periods in 2010. SG&A expenses for full year 2011 include $8.2 million of non-cash stock-based compensation expense. Total operating costs and expenses, excluding cost of sales, cost of license and other revenue and non-cash stock-based compensation expense, were $78.9 million for full year 2011, lower than the Company’s prior guidance of $82 to $84 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV